NCT02196701View on ClinicalTrials.gov

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

PHASE3CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 5, 2014

Primary Completion Date

March 17, 2017

Study Completion Date

March 17, 2017

Conditions
Psoriasis
Interventions
DRUG

Adalimumab

Administered by subcutaneous injection every other week.

DRUG

Methotrexate

Methotrexate was provided as 2.5 mg tablets for oral administration.

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY